COVID‐19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta‐analysis

Lee, Min Ho; Li, Han Jacob; Wasuwanich, Paul; Kim, Sung Eun; Kim, Jong Yeob; Jeong, Gwang Hun; Park, Seoyeon; Yang, Jae Won; Kim, Min Seo; Yon, Dong Keon; Lee, Seungwon; Koyanagi, Ai; Jacob, Louis; Kim, Eun Young; Cheon, Jae Hee; Smıth, Lee

doi:10.1002/rmv.2414

Cited by 11 publications

(8 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depending on the extent and severity of IBD, patients may receive treatment with 5-ASA, biologics, corticosteroids, thiopurines, or molecular-targeting agents. One of the most widely used drug classes is 5-ASA, which corresponds to the findings in our study [21][22][23][24]. Reports have shown that a SARS-CoV-2 infection may contribute to UC flares [25,26].…”

Section: Discussionsupporting

confidence: 90%

Exploring the Impact of COVID-19 on Ulcerative Colitis Patients: A Lifestyle Perspective

Straume,

Krūmiņa,

Elbere

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the new coronavirus that caused the coronavirus disease 2019 (COVID-19) outbreak. Studies have increasingly reported the involvement of organs outside the respiratory system, including the gastrointestinal tract. Data on the association between COVID-19 and ulcerative colitis (UC) are lacking. Materials and Methods: In this one-centre cross-sectional study, 49 patients with UC from the Riga East Clinical University Hospital outpatient clinic were included from June 2021 to December 2021. The patients were divided into two groups according to their history of a confirmed positive or negative COVID-19 status. Data on their lifestyle, diet, and medications and the food supplements used by the patients were collected during interviews and analysed using the R 4.2.1 software. Results: Out of 49 patients, 33 (63.3%) were male and 13 (36.7%) were female, with a mean age of 32.33 ± 8.6 years. Fourteen patients (28.6%) had a confirmed COVID-19 infection in the last year. The most common COVID-19-related symptoms were a fever and rhinorrhoea. A third of patients followed the inflammatory bowel disease diet (16; 32.7%); out of these patients, 12 (34.3%) did not contract COVID-19 (OR: 0.78 (0.18; 2.98), p > 0.05). In the COVID-19-positive group, the majority of patients did not use vitamin D (11; 79% vs. 3; 21%, (OR: 0.38 (0.07; 1.51), p = 0.28) or probiotics (11; 78.6% vs. 3; 21.4%, OR: 1.33 (0.23; 6.28), p = 0.7). In the COVID-19-positive group, most patients did not smoke (12; 85.7% vs. 2; 14.3%, p = 0.475) and did not use alcohol (9; 64.3% vs. 5; 35.7%, OR: 0.63 (0.16; 2.57), p = 0.5). Most of the patients who participated in sports activities were COVID-negative (18; 51.4% vs. 6; 42.9%, p = 0.82). Conclusions: There were no statistically significant differences in the use of food supplements, probiotics, or vitamins; the lifestyle habits; or the COVID-19 status in patients with UC.

show abstract

Section: Discussionsupporting

confidence: 90%

Exploring the Impact of COVID-19 on Ulcerative Colitis Patients: A Lifestyle Perspective

Straume,

Krūmiņa,

Elbere

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Although we did not observe significant differences between COVID-19 severity groups to these comorbidities, understanding risk factors for contracting SARS-CoV-2 remains crucial for managing COVID-19 outcomes. Identifying risk factors such as hypertension, obesity, inflammatory bowel disease, and other risk factors, enables the tailoring of preventive measures and treatments, potentially mitigating the severity and spread of the disease [31,32]. Furthermore, risk factor analysis is essential for identifying vulnerable populations, allowing healthcare providers to optimize resource allocation and enhance patient care strategies during the pandemic [33].…”

Section: Discussionmentioning

confidence: 99%

Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota

Galeeva,

Fedorov,

Starikova

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global healthcare, underscoring the importance of exploring the virus’s effects on infected individuals beyond treatments and vaccines. Notably, recent findings suggest that SARS-CoV-2 can infect the gut, thereby altering the gut microbiota. This study aimed to analyze the gut microbiota composition differences between COVID-19 patients experiencing mild and severe symptoms. We conducted 16S rRNA metagenomic sequencing on fecal samples from 49 mild and 43 severe COVID-19 cases upon hospital admission. Our analysis identified a differential abundance of specific bacterial species associated with the severity of the disease. Severely affected patients showed an association with Enterococcus faecium, Akkermansia muciniphila, and others, while milder cases were linked to Faecalibacterium prausnitzii, Alistipes putredinis, Blautia faecis, and additional species. Furthermore, a network analysis using SPIEC-EASI indicated keystone taxa and highlighted structural differences in bacterial connectivity, with a notable disruption in the severe group. Our study highlights the diverse impacts of SARS-CoV-2 on the gut microbiome among both mild and severe COVID-19 patients, showcasing a spectrum of microbial responses to the virus. Importantly, these findings align, to some extent, with observations from other studies on COVID-19 gut microbiomes, despite variations in methodologies. The findings from this study, based on retrospective data, establish a foundation for future prospective research to confirm the role of the gut microbiome as a predictive biomarker for the severity of COVID-19.

show abstract

“…An updated systematic review and meta-analysis by Lee et al [62] reported the susceptibility and clinical outcomes in IBD patients infected with SARS-CoV-2. IBD conditions were not associated with an increased risk of hospital or ICU admission or death, although 5-ASA and corticosteroids were associated with an increased risk for these events.…”

Section: Specific Digestive System Involvement In Covid-19 41 Pancrea...mentioning

confidence: 99%

SARS-CoV-2 Variant-Specific Gastrointestinal Symptoms of COVID-19: 2023 Update

Slabakova,

Gerasoudis,

Miteva

et al. 2023

Gastroenterology Insights

View full text Add to dashboard Cite

The gastrointestinal (GI) tract may be a significant entrance or interaction site for SARS-CoV-2; therefore, the gut mucosal immune system participates in virus interaction as a first-line physical and immunological defense, leading to GI involvement and symptoms. This review focuses on the GI symptoms associated with SARS-CoV-2 infection while providing specific results on variant-specific signs and syndromes related to coronavirus disease 2019 (COVID-19). The pattern of symptoms changed during the virus evolution, since the data provided a current and thorough picture of the symptoms experienced by SARS-CoV-2 infected people, and variations in symptom patterns occurred as the Alpha, Delta, and Omicron variants have spread. Since the beginning of the pandemic, GI symptoms have been linked to SARS-CoV-2 infections, even though most infected people do not report them. For example, diarrhea (28.2%) was the most frequently reported GI symptom in the early phase of the pandemic. The most observed GI tract symptoms during COVID-19 were anorexia (loss of appetite), nausea, vomiting, diarrhea, and abdominal pain, usually in at least one-third of the patients. Mesenteric ischemia and GI bleeding were less observed but more severe. While GI symptoms are not associated with increased mortality, they complicate the disease, increase the duration of the illness, and result in worse outcomes. Nevertheless, it is accepted that symptoms between variants differ significantly, i.e., the Omicron variant causes milder COVID-19 than the Delta. Still, the rate of GI symptoms has declined in the following variant-dominated phases of the pandemic (Alpha: 19.4%, Delta: 17.9%, Omicron: 13.8%), which was also demonstrated for other GI signs associated with COVID-19.

show abstract

COVID‐19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta‐analysis

Cited by 11 publications

References 78 publications

Exploring the Impact of COVID-19 on Ulcerative Colitis Patients: A Lifestyle Perspective

Exploring the Impact of COVID-19 on Ulcerative Colitis Patients: A Lifestyle Perspective

Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota

SARS-CoV-2 Variant-Specific Gastrointestinal Symptoms of COVID-19: 2023 Update

Contact Info

Product

Resources

About